Identification

Generic Name
Abetimus
DrugBank Accession Number
DB06662
Background

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Synonyms
  • Abetimus

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Abetimus.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Abetimus.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.
Allogeneic processed thymus tissueThe therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Abetimus.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Abetimus.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Abetimus.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent

Categories

ATC Codes
L04AA22 — Abetimus
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P3UVQ22SHK
CAS number
167362-48-3

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [Article]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [Article]
RxNav
1311600
Wikipedia
Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Lupus Nephritis / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentLupus Nephritis / Systemic Lupus Erythematosus (SLE)1
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at March 19, 2008 16:46 / Updated at February 21, 2021 18:52